- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim, Conmana (icotinib) / Betta Pharma
Retrospective data, Journal: The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. (Pubmed Central) - Apr 24, 2023 EGFR-TKIs must be carefully selected for the treatment of different histologic subtypes of NSCLC. For EGFR mutation (+) nonsquamous NSCLC, erlotinib is most likely to achieve the best OS and PFS, which makes it the first choice in the formulation of a treatment plan.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Extended physicochemical stability of cetuximab in opened vials and infusion bags when stored at 4 (Pubmed Central) - Apr 20, 2023 In conclusion, our newly developed positively and negatively selectable anti-HIV vectors have the potential to overcome the limitations of low engraftment of gene-modified HSPC for highly robust HIV-1 inhibition and an improved safety as a safety kill switch in cases of unexpected adverse effects caused by the genetically engineered cells. These results support the extended in-use shelf-life of cetuximab vials and bags, which can be cost-effective for healthcare providers.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Surgery, Metastases: Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer (clinicaltrials.gov) - Apr 14, 2023 P=N/A, N=15, Active, not recruiting, PTR improved the OS in patients with RAS wild-type synchronous left-sided colon or rectum cancer treated with cetuximab-containing chemotherapy regimens. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC (clinicaltrials.gov) - Apr 12, 2023 P2, N=215, Active, not recruiting, Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086). Trial primary completion date: Feb 2023 --> Jul 2023
- |||||||||| Journal: Top advances of the year: Head and neck cancer. (Pubmed Central) - Apr 11, 2023
However, in an important breakthrough for patients with nasopharyngeal cancer, the JUPITER-02 trial, conducted in China, Singapore, and Taiwan among patients with predominantly Epstein-Barr virus-related cancers, demonstrated a significant improvement in PFS (hazard ratio, 0.52) when toripalimab was added to gemcitabine/cisplatin chemotherapy. Immature survival data indicate overall survival will likely also be impacted.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Caffeine can alleviate non-alcoholic fatty liver disease by augmenting LDLR expression via targeting EGFR. (Pubmed Central) - Apr 5, 2023 In vitro, we found that caffeine could activate the EGFR-ERK1/2 signaling pathway in HepG2 cells, leading to increased LDLR mRNA and protein expression, and this effect could be inhibited by cetuximab...In summary, caffeine can enhance the LDLR expression by directly binding to EGFR and activating the EGFR-ERK1/2 signaling pathway. EGFR signaling may represent a novel target for the prevention and treatment of NAFLD.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Apr 5, 2023 P3, N=234, Recruiting, EGFR signaling may represent a novel target for the prevention and treatment of NAFLD. Unknown status --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Nov 2019 --> Nov 2025
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas. (Pubmed Central) - Apr 4, 2023 Therefore, this paper also summarized drug delivery methods through the BBB, including receptor-mediated transportation, nano-based carriers, and some physical and chemical methods for drug delivery. With these exciting advancements, more antibody-based therapies will likely enter clinical practice and allow more successful control of malignant gliomas.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: DOPE/CHEMS-Based EGFR-Targeted Immunoliposomes for Docetaxel Delivery: Formulation Development, Physicochemical Characterization and Biological Evaluation on Prostate Cancer Cells. (Pubmed Central) - Mar 30, 2023 Furthermore, we aimed to conjugate the monoclonal antibody cetuximab onto liposomal surface, as well as to thoroughly characterize the nanosystems and evaluate them on prostate cancer cells...Finally, the immunoliposome internalization was faster and greater than that of liposome in the DU145 cell line, with a higher EGFR overexpression. Thus, based on these results, it was possible to obtain a formulation with adequate characteristics of nanometric size, a high encapsulation of DTX and liposomes and particularly immunoliposomes containing DTX, which caused, as expected, a reduction in the viability of prostate cells, with high cellular internalization in EGFR overexpressing cells.
- |||||||||| Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Review, Journal: Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. (Pubmed Central) - Mar 30, 2023 Despite the improvement in safety properties of liposomal encapsulated DOX (in Doxil and Myocet), the efficacy is not superior to conventional DOX...Lyso-thermosensitive liposomal DOX (LTLD), MM-302, and C225-immunoliposomal(IL)-DOX have reached clinical trials...However, the fast clearance, the optimization of ligand density, stability, and release rate need more investigations. Therefore, we reviewed the latest approaches applied to deliver DOX more efficiently to the tumor, preserving the benefits obtained from FDA-approved liposomes.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Mar 29, 2023 P=N/A, N=27, Active, not recruiting, Therefore, we reviewed the latest approaches applied to deliver DOX more efficiently to the tumor, preserving the benefits obtained from FDA-approved liposomes. Trial completion date: Dec 2022 --> Mar 2025
- |||||||||| Tevimbra (tislelizumab) / BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Checkpoint inhibition, Metastases: Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC (clinicaltrials.gov) - Mar 28, 2023 P2, N=35, Active, not recruiting, Trial completion date: Dec 2022 --> Mar 2025 Recruiting --> Active, not recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
A Cascade of Trouble (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_3511; Two months after initiation she developed an inflammatory arthritis caused by an IRAE from Pembrolizumab and was initiated on a Prednisone taper but continued ICI treatment...An Aerobika and oscillating vest were given to assist with mucocilliary clearance and she resumed cancer directed therapy with Carboplatin/Fluorouracil/Cetuximab with no further progression of her TBM...Relapsing polychondritis is an exceedingly rare IRAE. The secondary manifestation of TBM presents a diagnostic and therapeutic challenge.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
P1/2 data, Clinical Trial,Phase I, Journal, Metastases: A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. (Pubmed Central) - Mar 24, 2023 P1/2 Concerns surrounding the safety and lack of preliminary evidence of improved anti-tumor activity of WNT974 + encorafenib + cetuximab, compared with previous encorafenib + cetuximab data, ultimately led to study discontinuation. Phase II was not initiated.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
COHESIN STROMAL ANTIGEN 1 (SA-1) LOSS CREATES THERAPEUTIC VULNERABILITY TO PARP-INHIBITOR IN COLORECTAL CANCER (S106 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_562; This may result through the regulation of genes involved in DNA repair including POLB and PARP4 in conjunction with vulnerability to chromatin looping challenges. Since the epigenetic loss of SA-1 is common in CRC, this synthetic lethality may have real potential for clinical impact.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
EGFR SIGNALING IN GASTRIC CHIEF CELL IS NECESSARY FOR THE PATHOGENESIS OF M (S105d - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_555; Our study shows that EGFR signaling in the chief cell is necessary for the pathogenesis of MD by inducing Jagged1 that activates Notch signaling. In addition, our data suggests that P1X/P2X and DBZ combination therapy is a promising treatment option for MD patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Adverse events, Metastases: Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study. (Pubmed Central) - Mar 21, 2023 P3 In addition, our data suggests that P1X/P2X and DBZ combination therapy is a promising treatment option for MD patients. This analysis indicated that, except for rare cases of nephrotoxicity, encorafenib+cetuximab is well tolerated in most patients, with most AEIs being mild-to-moderate in severity, occurring early and resolving rapidly.
|